Acton Pharmaceuticals of Marlborough announced that its asthma inhaler does not inhibit growth in children, as some treatments are thought to do.
Acton’s study involved more than 200 children and showed no signs of growth being impaired from using the company’s product.
The company hopes to commercialize its Aerospan therapy after certain manufacturing requirements are met.
